Meeting
2022 ASCO Annual Meeting
Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab-FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212).
Authors
Beeke Hoppe
Charité - Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany
Beeke Hoppe , Dominik Paul Modest , Luisa Keilholz , Il-Kang Na , Meinolf Karthaus , Stefan Fruehauf , Ullrich Graeven , Ludwig Fischer Von Weikersthal , Eray Goekkurt , Anke C. Reinacher-Schick , Stefan Kasper , Andreas Jay Kind , Annika Kurreck , Swantje Held , Volker Heinemann , David Horst , Armin Jarosch , Sebastian Stintzing , Tanja Trarbach , Arndt Stahler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3537)
DOI
10.1200/JCO.2022.40.16_suppl.3537
Abstract #
3537
Poster Bd #
331
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Predictive and prognostic value of carcinoembryonic antigen (CEA) on maintenance therapy with 5-fluoruracil/leucovorin plus panitumumab or 5-fluoruracil/leucovorin alone in RAS wildtype metastatic colorectal cancer: Evaluation of the phase II PanaMa trial (AIO KRK 0212).
First Author: Annika Kurreck
Poster
2022 ASCO Annual Meeting
Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KRK-0212, maintenance therapy with 5-FU, folinic acid (FU/FA) with or without panitumumab).
First Author: Andreas Jay Kind
Poster
2022 ASCO Annual Meeting
Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212).
First Author: Kathrin Heinrich
Poster
2015 Gastrointestinal Cancers Symposium
A phase II trial of panitumumab with irinotecan and S-1 (IRIS) as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer.
First Author: Rai Shimoyama